Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer

Published:2013-01-08 Issue:2 Volume:16 Page:123-131
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Sanchez C,Chan R,Bajgain P,Rambally S,Palapattu G,Mims M,Rooney C M,Leen A M,Brenner M K,Vera J F

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/pcan201249.pdf

Reference58 articles.

1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411–422.

2. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089–3094.

3. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670–3679.

4. Karan D, Holzbeierlein JM, Van Veldhuizen P, Thrasher JB . Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol 2012; 9: 376–385.

5. Longo DL . New therapies for castration-resistant prostate cancer. N Engl J Med 2010; 363: 479–481.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High Pretreatment DHEA Is Associated with Inferior Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer;Cancers;2024-03-14

2. Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy;Journal of Cancer;2024

3. Combination Immunotherapy in Prostate Cancer;Cancers;2022-12-08

4. Tumor buster - where will the CAR-T cell therapy ‘missile’ go?;Molecular Cancer;2022-10-19

5. The Cellular and Molecular Immunotherapy in Prostate Cancer;Vaccines;2022-08-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3